Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? A randomised controlled trial

BMC Medicine

Hayden McRobbie¹  Al-Rehan Dhanji²  Katie Myers Smith¹  Peter Hajek¹ 

[1]UK Centre for Tobacco Control Studies, Wolfson Institute of Preventive Medicine, Barts & The London School of Medicine and Dentistry, Queen Mary, University of London, London Newark Street, London E1 2AT, UK

[2]Barts and The London NHS Trust, London, UK

关键词: Nicotine patch;    Varenicline;    Smoking cessation;   

Others  :  857008
DOI  :  10.1186/1741-7015-11-140

 received in 2013-01-25, accepted in 2013-03-15,  发布年份 2013

【 摘 要 】

Background

Nicotine replacement therapy (NRT) and varenicline are both effective in helping smokers quit. There is growing interest in combining the two treatments to improve treatment outcomes, but no experimental data exist on whether this is efficacious. This double-blind randomised controlled trial was designed to evaluate whether adding nicotine patches to varenicline improves withdrawal relief and short-term abstinence rates.

Methods

117 participants seeking help to stop smoking were randomly allocated to varenicline plus placebo patch or varenicline plus nicotine patch (15 mg/16 hour). Varenicline use commenced one week prior to the target quit date (TQD), patch use started on the TQD. Ratings of urges to smoke and cigarette withdrawal symptoms were collected weekly over 4 weeks post-TQD. Medication use and smoking status were established at 1, 4 and 12 weeks. Participants lost to follow-up were included as continuing smokers.

Results

92% of participants used both medications during the first week after the TQD. The combination treatment generated no increase in nausea or other adverse effects. It had no overall effect on urges to smoke or on other withdrawal symptoms. The combination treatment did not improve biochemically validated abstinence rates at 1 week and 4 weeks post-TQD (69% vs 59%, p=0.28 and 60% vs 59%, p=0.91, in the nicotine patch and placebo patch arm, respectively), or self reported abstinence rates at 12 weeks (36% vs. 29%, p=0.39, NS).

Conclusions

The efficacy of varenicline was not enhanced by the addition of nicotine patches, although further trials would be useful to exclude the possibility of type II error.

Trial Registration

Clinicaltrials.gov Registration Number: NCT01184664

【 授权许可】

   
2013 Hajek et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Stead LF, Perera R, Bullen C, Mant D, Lancaster T: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008., 1CD000146
• [2]Cahill K, Stead LF, Lancaster T: Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2011., 2CD006103
• [3]Bauld L, Bell K, McCullough L, Richardson L, Greaves L: The effectiveness of NHS smoking cessation services: a systematic review. J Public Health (Oxf) 2009, 32:71-82.
• [4]Ebbert JO, Burke MV, Hays JT, Hurt RD: Combination treatment with varenicline and nicotine replacement therapy. Nicotine Tob Res 2009, 11:572-576.
• [5]Hajek P, McRobbie HJ, Myers KE, Stapleton J, Dhanji AR: Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates. Arch Intern Med 2011, 171:770-777.
• [6]Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR, et al.: Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006, 296:47-55.
• [7]Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR, Varenicline Phase 3 Study G: Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006, 296:56-63.
• [8]Aubin HJ, Bobak A, Britton JR, Oncken C, Billing CB Jr, Gong J, Williams KE, Reeves KR: Varenicline versus transdermal nicotine patch for smoking cessation: Results from a randomised, open-label trial. Thorax 2008, 63:717-724.
• [9]West R, Baker CL, Cappelleri JC, Bushmakin AG: Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology (Berl) 2008, 197:371-377.
• [10]Shiffman S, Ferguson SG: Nicotine patch therapy prior to quitting smoking: a meta-analysis. Addiction 2008, 103:557-563.
• [11]Lindson N, Aveyard P: An updated meta-analysis of nicotine preloading for smoking cessation: investigating mediators of the effect. Psychopharmacology (Berl) 2011, 214:579-592.
• [12]Prochaska JJ, Hilton JF: Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 2012, 344:e2856.
• [13]Health T, Centre SCI: Statistics on NHS Stop Smoking Services: England, April 2010 – March 2011. London: The Information Centre, Lifestyle Statistics; 2011.
• [14]Stapleton JA, Watson L, Spirling LI, Smith R, Milbrandt A, Ratcliffe M, Sutherland G: Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 2008, 103:146-154.
• [15]McEwen A, Hajek P, McRobbie H, West R: Manual Of Smoking Cessation: A Guide For Counsellors And Practitioners. Oxford: Blackwell Publishing; 2006.
• [16]Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO: The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991, 86:1119-1127.
• [17]West R, Hajek P: Evaluation of the mood and physical symptoms scale (MPSS) to assess cigarette withdrawal. Psychopharmacology (Berl) 2004, 177:195-199.
• [18]Fiore MC, Smith SS, Jorenby DE, Baker TB: The effectiveness of the nicotine patch for smoking cessation, A meta-analysis. JAMA 1994, 271:1940-1947.
• [19]McRobbie H, Hajek P: Effects of rapid smoking on post-cessation urges to smoke. Addiction 2007, 102:483-489.
• [20]West R, Hajek P, Stead L, Stapleton J: Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 2005, 100:299-303.
• [21]Shiffman S, Ferguson SG: The effect of a nicotine patch on cigarette craving over the course of the day: results from two randomized clinical trials. Curr Med Res Opin 2008, 24:2795-2804.
• [22]Hajek P, West R, Foulds J, Nilsson F, Burrows S, Meadow A: Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med 1999, 159:2033-2038.
• [23]Farley AC, Hajek P, Lycett D, Aveyard P: Interventions for preventing weight gain after smoking cessation. Cochrane database of systematic reviews (Online) 2012, 1:CD006219.